Company Quick10K Filing
Sono Tek
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 15 $31
10-Q 2020-01-14 Quarter: 2019-11-30
10-Q 2019-07-15 Quarter: 2019-05-31
10-K 2019-05-28 Annual: 2019-02-28
10-Q 2019-01-14 Quarter: 2018-11-30
10-Q 2018-10-15 Quarter: 2018-08-31
10-Q 2018-07-16 Quarter: 2018-05-31
10-K 2018-05-24 Annual: 2018-02-28
10-Q 2018-01-16 Quarter: 2017-11-30
10-Q 2017-10-16 Quarter: 2017-08-31
10-Q 2017-07-17 Quarter: 2017-05-31
10-K 2017-05-26 Annual: 2017-02-28
10-Q 2017-01-17 Quarter: 2016-11-30
10-Q 2016-10-17 Quarter: 2016-08-31
10-Q 2016-07-15 Quarter: 2016-05-31
10-K 2016-05-25 Annual: 2016-02-29
10-Q 2016-01-14 Quarter: 2015-11-30
10-Q 2015-10-15 Quarter: 2015-08-31
10-Q 2015-07-15 Quarter: 2015-05-31
10-K 2015-05-27 Annual: 2015-02-28
10-Q 2015-01-14 Quarter: 2014-11-30
10-Q 2014-10-15 Quarter: 2014-08-31
10-Q 2014-07-15 Quarter: 2014-05-31
10-K 2014-05-28 Annual: 2014-02-28
10-Q 2014-01-14 Quarter: 2013-11-30
10-Q 2013-10-15 Quarter: 2013-08-31
10-K 2013-05-22 Annual: 2013-02-28
10-Q 2013-01-14 Quarter: 2012-11-30
10-Q 2012-10-11 Quarter: 2012-08-31
10-Q 2012-07-12 Quarter: 2012-05-31
10-K 2012-05-11 Annual: 2012-02-29
10-Q 2012-01-13 Quarter: 2011-11-30
10-Q 2011-10-14 Quarter: 2011-08-31
10-Q 2011-07-11 Quarter: 2011-05-31
10-K 2011-05-23 Annual: 2011-02-28
10-Q 2011-01-12 Quarter: 2010-11-30
10-Q 2010-10-05 Quarter: 2010-08-31
10-Q 2010-07-12 Quarter: 2010-05-31
10-K 2010-05-24 Annual: 2010-02-28
10-Q 2010-01-12 Quarter: 2009-11-30
8-K 2020-01-14 Earnings, Regulation FD, Exhibits
8-K 2019-10-14 Earnings, Regulation FD, Exhibits
8-K 2019-08-22 Earnings, Regulation FD, Exhibits
8-K 2019-08-22 Shareholder Vote
8-K 2019-03-14 Earnings, Regulation FD, Exhibits
8-K 2019-03-07 Amend Bylaw, Exhibits
8-K 2019-01-17 Enter Agreement
8-K 2019-01-16 Other Events
8-K 2019-01-14 Earnings, Regulation FD, Exhibits
8-K 2018-12-10 Other Events
8-K 2018-11-29 Earnings, Regulation FD, Exhibits
8-K 2018-11-15 Officers, Exhibits
8-K 2018-10-15 Earnings, Regulation FD, Exhibits
8-K 2018-08-23 Shareholder Vote
8-K 2018-08-23 Earnings, Regulation FD, Exhibits
8-K 2018-07-16 Earnings, Regulation FD, Exhibits
8-K 2018-01-16 Earnings, Regulation FD, Exhibits
SOTK 2019-11-30
Note 1: Business Description
Note 2: Significant Accounting Policies
Note 3: Revenue Recognition
Note 4: Inventories
Note 5: Stock Options
Note 6: Stock Based Compensation
Note 7: Earnings per Share
Note 8: Long Term Debt
Note 9: Revolving Line of Credit
Note 10: Commitments and Contingencies
Note 11: Subsequent Events
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3 - Quantitative and Qualitative Disclosures About Market Risk
Item 4 - Controls and Procedures
Part II - Other Information
EX-31.1 ex31-1.htm
EX-31.2 ex31-2.htm
EX-32.1 ex32-1.htm
EX-32.2 ex32-2.htm

Sono Tek Earnings 2019-11-30

SOTK 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

Comparables ($MM TTM)
Ticker M Cap Assets Liab Rev G Profit Net Inc EBITDA EV G Margin EV/EBITDA ROA
CRMZ 32 16 13 14 4 0 0 24 30% 88.1 0%
SING 32 2 9 2 1 -16 -15 34 34% -2.3 -698%
GHSI 32 6 1 1 1 -8 -8 29 59% -3.9 -141%
GLTC 32 3 5 1 1 -4 -4 36 57% -10.0 -141%
CANN 32 4 5 5 4 -16 -16 32 74% -2.0 -364%
SOTK 31 13 4 12 5 0 1 30 45% 55.0 1%
KNWN 31 3 4 3 1 -4 -3 29 21% -10.8 -114%
CANB 31 5 0 1 1 -5 -5 31 48% -6.6 -86%
DRNE 31 5 3 3 1 -7 -6 30 33% -4.8 -146%
TGLO 31 0 0 -0 -0 31 -138.7 22,235,900%

10-Q 1 eps8770.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: November 30, 2019

 

OR

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File No.: 0-16035

 

 

(Exact name of registrant as specified in its charter)

 

New York 14-1568099
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)

 

2012 Rt. 9W, Milton, NY 12547

(Address of Principal Executive Offices) (Zip Code)

 

Issuer's telephone no., including area code: (845) 795-2020

 

Securities Registered Pursuant to Section 12(b) of the Act: None

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
None N/A N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES     NO 

Indicate by checkmark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes     No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer Accelerated Filer
Non-Accelerated Filer Smaller reporting company
  Emerging Growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES     NO 

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

 

    Outstanding as of January 14, 2020
Class    
Common Stock, par value $.01 per share     15,323,831

 

 

SONO-TEK CORPORATION

 

 

INDEX

 

  Page
Part I - Financial Information  
   
Item 1 – Condensed Consolidated Financial Statements: 1 - 3
   
Condensed Consolidated Balance Sheets – November 30, 2019 (Unaudited) and February 28, 2019 1
   
Condensed Consolidated Statements of Operations – Nine and Three Months Ended November 30, 2019 and 2018 (Unaudited) 2
   
Condensed Consolidated Statements of Stockholders Equity – Nine and Three Months Ended November 30, 2019 and 2018 (Unaudited) 3
   
Condensed Consolidated Statements of Cash Flows – Nine Months Ended November 30, 2019 and 2018 (Unaudited) 4
   
Notes to Condensed Consolidated Financial Statements 5- 9
   
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 10–16
   
Item 3 – Quantitative and Qualitative Disclosures about Market Risk 17
   
Item 4 – Controls and Procedures 17
   
Part II - Other Information 18
   
Signatures and Certifications 19

 

 

 

SONO-TEK CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   November 30,     
   2019   February 28, 
   (Unaudited)   2019 
ASSETS          
           
Current Assets:          
Cash and cash equivalents  $2,279,506   $3,144,123 
Marketable securities   3,739,935    2,365,706 
Accounts receivable (less allowance of $46,000)   1,338,320    1,397,891 
Inventories, net   2,978,780    1,658,016 
Prepaid expenses and other current assets   193,552    395,005 
Total current assets   10,530,093    8,960,741 
           
Land   250,000    250,000 
Buildings, net   1,673,275    1,731,547 
Equipment, furnishings and building improvements, net   975,835    802,932 
Intangible assets, net   110,453    122,941 
Deferred tax asset   332,017    332,017 
           
TOTAL ASSETS  $13,871,673   $12,200,178 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current Liabilities:          
Accounts payable  $919,455   $585,694 
Accrued expenses   767,971    632,706 
Customer deposits   1,953,826    1,149,558 
Current maturities of long term debt   167,929    162,816 
Income taxes payable   24,744    6,272 
Total current liabilities   3,833,925    2,537,046 
           
Deferred tax liability   370,757    370,757 
Long term debt, less current maturities   581,065    707,715 
Total liabilities   4,785,747    3,615,518 
           
Commitments and Contingencies  (Note 10)        
           
Stockholders’ Equity          
Common stock, $.01 par value; 25,000,000 shares authorized, 15,323,831 and 15,197,563 shares issued and outstanding, at November 30 and February 28, respectively   153,238    151,976 
Additional paid-in capital   9,009,979    8,929,607 
Accumulated deficit   (77,291)   (496,923)
Total stockholders’ equity   9,085,926    8,584,660 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $13,871,673   $12,200,178 

 

See notes to unaudited condensed consolidated financial statements.

1 

 

SONO-TEK CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   Nine Months Ended
November 30,
   Three Months Ended
November 30,
 
   2019   2018   2019   2018 
                 
Net Sales  $9,840,536   $8,673,849   $3,672,286   $3,155,258 
Cost of Goods Sold   5,191,929    4,761,919    1,875,606    1,858,970 
        Gross Profit   4,648,607    3,911,930    1,796,680    1,296,288 
                     
Operating Expenses                    
Research and product development costs   1,020,299    978,733    361,429    324,969 
Marketing and selling expenses   2,326,115    1,979,365    849,419    652,664 
General and administrative costs   935,693    857,832    316,218    268,632 
            Total Operating Expenses   4,282,107    3,815,930    1,527,066    1,246,265 
                     
Operating Income   366,500    96,000    269,614    50,023 
                     
Interest Expense   (25,465)   (30,501)   (8,000)   (9,684)
Interest and Dividend Income   77,496    104,686    20,513    33,164 
Realized gain on sale of marketable securities       119,075         
Net unrealized loss on marketable securities       (189,016)       (59,359)
Other income   24,404    28,196    7,527    8,681 
                     
Income Before Income Taxes   442,935    128,440    289,654    22,825 
                     
Income Tax Expense   23,303    27,627    10,000    2,566 
                     
Net Income  $419,632   $100,813   $279,654   $20,259 
                     
Basic Earnings Per Share  $0.03   $0.01   $0.02   $0.00 
                     
Diluted Earnings Per Share  $0.03   $0.01   $0.02   $0.00 
                     
Weighted Average Shares - Basic   15,291,968    15,078,933    15,306,008    15,164,440 
                     
Weighted Average Shares - Diluted   15,354,472    15,284,071    15,371,819    15,386,094 

 

See notes to unaudited condensed consolidated financial statements.

 

2 

 

SONO-TEK CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

NINE AND THREE MONTHS ENDED NOVEMBER 30, 2019 AND 2018

 

Nine Months Ended November 30, 2019 and 2018

 

   Common Stock
Par Value $.01
   Additional
Paid – In
   Accumulated
Other Comprehensive
   Accumulated   Total
Stockholders’
 
   Shares   Amount   Capital   Income (Loss)   Deficit   Equity 
Balance – February 28, 2019   15,197,563   $151,976   $8,929,607   $   $(496,923)  $8,584,660 
Cashless exercise of stock options   126,268    1,262    (1,262)              
Stock based compensation expense             81,634              81,634 
Net Income                       419,632    419,632 
Balance – November 30, 2019 (unaudited)   15,323,831   $153,238   $9,009,979   $   $(77,291)  $9,085,926 
                               
Balance – February 28, 2018   14,986,367   $149,864   $8,901,171   $101,605   $(760,115)  $8,392,525 
Reclassification of unrealized gain on marketable securities upon adoption of ASU 2016-01                  (101,605)   101,605     
Cashless exercise of stock options   205,358    2,054    (2,054)              
Stock based compensation expense             22,777              22,777 
Net income                       100,813    100,813 
Balance – November 30, 2018 (unaudited)   15,191,725   $151,918   $8,921,894   $   $(557,697)  $8,516,115 

 

Three Months Ended November 30, 2019 and 2018

 

   Common Stock
Par Value $.01
   Additional
Paid – In
   Accumulated
Other Comprehensive
   Accumulated   Total
Stockholders’
 
   Shares   Amount   Capital   Income (Loss)   Deficit   Equity 
Balance – August 31, 2019 (unaudited)   15,301,613   $153,016   $8,972,394   $   $(356,945)  $8,768,465 
Cashless exercise of stock options   22,218    222    (222)              
Stock based compensation expense             37,807              37,807 
Net income                       279,654    279,654 
Balance – November 30, 2019 (unaudited)   15,323,831   $153,238   $9,009,979   $   $(77,291)  $9,085,926 
                               
Balance – August 31, 2018 (unaudited)   15,155,560   $151,556   $8,915,873   $   $(577,956)  $8,489,473 
Cashless exercise of stock options   36,165    362    (362)              
Stock based compensation expense             6,383              6,383 
Net income                       20,259    20,259 
Balance – November 30, 2018 (unaudited)   15,191,725   $151,918   $8,921,894   $   $(557,697)  $8,516,115 

 

See notes to unaudited condensed consolidated financial statements.

 

 

3 

 

SONO-TEK CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   Unaudited 
   Nine Months Ended
November 30,
 
   2019   2018 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net Income  $419,632   $100,813 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   290,203    256,519 
Stock based compensation expense   81,634    22,777 
Inventory reserve   50,000    48,000 
Unrealized loss on marketable securities       189,016 
Decrease (Increase) in:          
Accounts receivable   59,571    (388,538)
Inventories   (1,370,764)   (436,802)
Prepaid expenses and other current assets   201,453    (150,391)
(Decrease) Increase in:          
Accounts payable and accrued expenses   469,026    (99,748)
Customer Deposits   804,268    620,303 
Income taxes payable   18,472    (73,800)
Net Cash Provided by Operating Activities   1,023,495    88,149 
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of equipment and furnishings   (392,346)   (486,711)
Sale (purchase) of marketable securities   (1,374,229)   125,534 
Net Cash Used in Investing Activities   (1,766,575)   (361,177)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Repayment of long term debt   (121,537)   (116,555)
Net Cash Used In Financing Activities   (121,537)   (116,555)
           
NET DECREASE IN CASH AND CASH EQUIVALENTS   (864,617)   (389,583)
           
CASH AND CASH EQUIVALENTS          
Beginning of period   3,144,123    2,016,464 
End of period  $2,279,506   $1,626,881 
           
SUPPLEMENTAL CASH FLOW DISCLOSURE:          
Interest paid  $25,465   $30,501 
Income Taxes Paid  $4,831   $101,426 

 

 

See notes to unaudited condensed consolidated financial statements.

4 

 

 

SONO-TEK CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NINE MONTHS ENDED November 30, 2019 and 2018

(Unaudited)

 

NOTE 1: BUSINESS DESCRIPTION

 

Sono-Tek Corporation (the “Company”, “Sono-Tek”, “We” or “Our”) is the world leader in the design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to protect, strengthen or smooth surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. We design and manufacture custom-engineered ultrasonic coating systems and also provide patented nozzles and generators for manufacturers’ equipment.

 

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, the Condensed Consolidated Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, all adjustments considered necessary for a fair presentation (consisting of normal recurring adjustments) have been included. The results for the interim periods are not necessarily indicative of what the results will be for the fiscal year. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements as of and for the fiscal year ended February 28, 2019 (“fiscal year 2019”) contained in the Company’s 2019 Annual Report on Form 10-K filed with the SEC. The Company’s current fiscal year ends on February 29, 2020 (“fiscal 2020”).

 

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

 

Cash and Cash Equivalents - Cash and cash equivalents consist of money market mutual funds, short term commercial paper and short-term certificates of deposit with original maturities of 90 days or less.

 

Consolidation - The accompanying condensed consolidated financial statements of the Company, include the accounts of the Company and its wholly owned subsidiary, Sono-Tek Industrial Park, LLC (“SIP”). SIP operates as a real estate holding company for the Company’s real estate operations.

 

Earnings Per Share - Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock.

 

Equipment, Furnishings and Leasehold Improvements – Equipment, furnishings and leasehold improvements are stated at cost. Depreciation of equipment and furnishings is computed by use of the straight-line method based on the estimated useful lives of the assets, which range from three to five years.

 

Fair Value of Financial Instruments - The Company follows the guidance in the “Fair Value Measurements and Disclosure Topic” of the Accounting Standards Codification for assets and liabilities measured at fair value on a recurring basis. This guidance establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, the guidance requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

 

Level 1: Quoted prices in active markets.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

5 

 

 

The fair values of financial assets of the Company were determined using the following categories at November 30, 2019 and February 28, 2019, respectively:

 

   Quoted Prices in Active Markets 
   (Level 1) 
   November 30,
2019
   February 28,
2019
 
Marketable Securities  $3,739,935   $2,365,706 

 

Marketable Securities include mutual funds, certificates of deposit and US Treasury securities of $3,739,935 and $2,365,706 that are considered to be highly liquid and easily tradeable as of November 30, 2019, and February 28, 2019, respectively. These securities are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the Company’s fair value hierarchy. The Company’s marketable securities are considered to be available-for-sale investments as defined under ASC 320 “Investments – Debt and Equity Securities.”

 

Income Taxes - The Company accounts for income taxes under the asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences of "temporary differences" by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized.

 

Intangible Assets - Include costs of patent applications which are deferred and charged to operations over seventeen years for domestic patents and twelve years for foreign patents. The accumulated amortization of patents is $168,516 and $160,433 at November 30, 2019 and February 28, 2019, respectively. Annual amortization expense of such intangible assets is expected to be approximately $11,000 per year for the next five years.

 

Interim Reporting - The attached summary condensed consolidated financial information does not include all disclosures required to be included in a complete set of financial statements prepared in conformity with accounting principles generally accepted in the United States of America. Such disclosures were included with the financial statements of the Company at February 28, 2019, and included in its report on Form 10-K. Such statements should be read in conjunction with the data herein.

 

The financial information reflects all adjustments, normal and recurring, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results for such interim periods are not necessarily indicative of the results to be expected for the year.

 

Inventories - Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method for raw materials, subassemblies and work-in-progress and the specific identification method for finished goods.

 

Land and Buildings – Land and buildings are stated at cost. Buildings are being depreciated by use of the straight-line method based on an estimated useful life of forty years.

 

Long-Lived Assets - The Company periodically evaluates the carrying value of long-lived assets, including intangible assets, when events and circumstances warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated undiscounted cash flow from such asset is separately identifiable and is less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair market value of the long-lived asset. Fair market value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved.

 

Management Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

6 

 

 

Marketable Securities - The Company adopted ASU 2016-01, “Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset, and eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. The Company has evaluated the potential impact this standard may have on the condensed consolidated financial statements and the fair value allowance of the securities from the prior year has been reclassified to Retained Earnings from Other Accumulated Comprehensive Income. The unrealized loss on the marketable securities during the three and nine months ended November 30, 2018 has been disclosed a separate line item on the Income Statement.

 

New Accounting Pronouncements-

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), to increase transparency and comparability among organizations by recognizing a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either operating or financing, with such classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, and early adoption is permitted. The adoption of ASU 2016-02 had no material impact on the Company’s financial statements.

 

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220), “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. ASU 2018-02 was issued to allow the reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effect resulting from the Tax Cuts and Jobs Act enacted on December 22, 2017. The Tax Cuts and Jobs Act, among other things, reduced the corporate tax rate from 35% to 21%, which required the re-evaluation of any deferred tax assets and liabilities at the lowered tax rate which potentially could leave a disproportionate tax effect in accumulated other comprehensive income. ASU 2018-02 allows for the election to reclassify these stranded tax effects to retained earnings. ASU 2018-02 is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period for public business entities for reporting periods for which financials statements have not yet been issued. The adoption of ASU 2018-02 had no material impact on the Company’s financial statements.

 

Other than Accounting Standards Update (“ASU”) ASU 2016-02 and ASU 2018-02 discussed above, all new accounting pronouncements issued but not yet effective have been deemed to be not applicable to the Company. Hence, the adoption of these new accounting pronouncements, once effective, is not expected to have an impact on the Company.

 

Reclassifications – Where appropriate, certain reclassifications have been made to the prior period to conform to the presentations of the current period.

 

NOTE 3: REVENUE RECOGNITION

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), to clarify the principles of recognizing revenue and create common revenue recognition guidance between U.S. GAAP and International Financial Reporting Standards. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized at an amount that reflects the consideration expected to be received in exchange for such goods or services. In addition, ASU 2014-09 requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The ASU is effective for fiscal years beginning after December 15, 2017.

 

The new revenue standard is principle based and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice, and guidance may evolve as companies and the accounting profession work to implement this new standard. The implementation of the standard did not have a material impact on the financial statements.

 

7 

 

A majority of the Company’s sales revenue is derived primarily from short term contracts with customers, which, on average, are in effect for less than twelve months. Sales revenue from manufactured equipment transferred at a single point in time accounts for a majority of the Company’s revenue.

 

Sales revenue is recognized when control of the Company’s manufactured equipment is transferred to its customers, in an amount that reflects the consideration the Company expects to receive based upon the agreed transaction price. The Company’s performance obligations are satisfied when its customers take control of the purchased equipment, which is based on the contract terms. Based on prior experience, the Company reasonably estimates its sales returns and warranty reserves. Sales are presented net of discounts and allowances. Discounts and allowances are determined when a sale is negotiated. The Company does not grant its customers or independent representatives, the ability to return equipment nor does it grant price adjustments after a sale is complete.

 

The Company does not capitalize any sales commission costs related to the acquisition of a contract. All commissions related to a performance obligation that are satisfied at a point in time are expensed when the customer takes control of the purchased equipment.

 

At November 30, 2019, the Company had received $1,954,000 in cash deposits, and had issued Letters of Credit in the amount of $659,000 to secure these cash deposits. The Company was utilizing $659,000 of its available credit line to collateralize these letters of credit. The Company’s inventory included approximately $707,000 directly related to servicing these customer contracts.

 

NOTE 4: INVENTORIES

 

Inventories consist of the following:

 

   November 30,   February 28, 
   2019   2019 
Raw materials and subassemblies  $1,050,183   $873,483 
Finished goods   598,218    571,640 
Contracts in process inventory   706,582     
Work in process   802,077    483,271 
Total   3,157,060    1,928,394 
Less: Allowance   (178,280)   (270,378)
Net inventories  $2,978,780   $1,658,016 

 

NOTE 5: STOCK OPTIONS

 

Stock Options – Under the 2013 Stock Incentive Plan ("2013 Plan"), options can be granted to officers, directors, consultants and employees of the Company and its subsidiaries to purchase up to 2,500,000 shares of the Company's common stock. Under the 2013 Plan options expire ten years after the date of grant. As of November 30, 2019, there were 546,667 options outstanding under the 2013 Plan.

 

Under the 2003 Stock Incentive Plan, as amended ("2003 Plan"), until May 2013, options were available to be granted to officers, directors, consultants and employees of the Company and its subsidiaries to purchase up to 1,500,000 shares of the Company's common stock. As of November 30, 2019, there were 50,000 options outstanding under the 2003 Plan, under which no additional options may be granted.

 

During the nine months ended November 30, 2019, 228,833 options were exercised on a cashless basis into 126,268 shares of common stock.

 

NOTE 6: STOCK BASED COMPENSATION

 

The Company adopted ASC 718, “Share Based Payments.” which requires companies to expense the value of employee stock options and similar awards.

 

During the three months ended November 30, 2019, the Company granted options to acquire 7,500 shares to employees exercisable at $2.10 and options for 100,000 shares to an officer with an exercise price of $2.65. The options granted to employees vest over three years and expire in ten years. The options granted to the officer vested upon grant and expire in ten years. All of the options granted by the Company during the three months ended November 30, 2019 had a combined weighted average grant date fair value of $0.32 per share.

 

8 

 

 

During the nine months ended November 30, 2019, the Company granted options to acquire 17,500 shares to employees exercisable at prices ranging from $2.10 to $2.65, options to acquire 20,000 shares to the non-employee members of the board of directors with an exercise price of $2.65 and options for 200,000 shares to an officer and director exercisable at prices of ranging from $2.45 to $2.65. The options granted to employees and directors vest over three years and expire in ten years. The options granted to the officer vested upon grant and expire in ten years. All of the options granted by the Company during the nine months ended November 30, 2019 had a combined weighted average grant date fair value of $0.34 per share.

 

The weighted-average fair value of options are estimated on the date of grant using the Black-Scholes options-pricing model. The weighted-average Black-Scholes assumptions are as follows:

 

  Nine Months Ended
November 30, 2019
Expected Life 1-8 years
Risk free interest rate 1.58% - 2.05%
Expected volatility 27.46% - 32.24%
Expected dividend yield 0%

 

In computing the impact, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk free interest rate; volatility; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.

 

For the three and nine months ended November 30, 2019 and 2018, net income and earnings per share reflect the actual deduction for stock-based compensation expense. The impact of applying ASC 718 approximated $38,000 and $7,000 in additional compensation expense during the three months ended November 30, 2019 and 2018, respectively. The impact of applying ASC 718 approximated $82,000 and $23,000 in additional compensation expense during the nine months ended November 30, 2019 and 2018, respectively. Such amounts are included in general and administrative expenses on the statement of operations. The expense for stock-based compensation is a non-cash expense item.

 

NOTE 7: EARNINGS PER SHARE

 

The denominators for the calculation of diluted earnings per share at November 30, 2019 and 2018 are calculated as follows:

 

    Nine Months Ended     Three Months Ended  
    November 30,     November 30,  
    2019     2018     2019     2018  
Numerator for basic and diluted earnings per share   $ 419,632     $ 100,813     $ 279,654     $ 20,259  
                                 
Denominator for basic earnings per share – weighted average     15,291,968       15,078,933       15,306,008       15,164,440  
                                 
Effects of dilutive securities                                
                                 
Stock options for employees, directors and outside consultants     62,504       205,138       65,811       221,654  
                                 
Denominator for diluted earnings per share     15,354,472       15,284,071       15,371,819       15,386,094  
                                 
Basic earnings per share   $ 0.03     $ 0.01     $ 0.02     $ 0.00  
Diluted earnings per share   $ 0.03     $ 0.01     $ 0.02     $ 0.00  

 

9 

 

 

NOTE 8: LONG TERM DEBT

 

Long-term debt consists of the following:

 

    November 30,     February 28,  
    2019     2019  
             
Note payable, bank, collateralized by land and buildings, payable in monthly installments of principal and interest of $16,358 through January 2024 with an interest rate of 4.15% and a 10-year term.   $ 748,994     $ 870,531  
                 
Total long term debt     748,994       870,531  
Due within one year     167,929       162,816  
Due after one year   $ 581,065     $ 707,715  

 

NOTE 9: REVOLVING LINE OF CREDIT

 

The Company has a $1,500,000 revolving line of credit at prime which was 4.75% at November 30, 2019. The revolving credit line is collateralized by the Company’s accounts receivable and inventory. The line of credit is payable on demand and must be retired for a 30-day period, once annually. If the Company fails to perform the 30-day annual pay down or if the bank elects to terminate the credit line, the bank may, at its option, convert the outstanding balance to a 36-month term note with payments including interest in 36 equal installments.

 

As of November 30, 2019, $659,000 of the Company’s credit line was being utilized to collateralize letters of credit issued to customers that have remitted cash deposits to the Company on existing orders. The letters of credit expire in 2020. As of November 30, 2019, there were no outstanding borrowings under the line of credit and the unused portion of the credit line was $841,000 as of November 30, 2019.

 

NOTE 10: COMMITMENTS AND CONTINGENCIES

 

Other than the letters of credit disclosed in Note 9, the Company did not have any material commitments or contingencies as of November 30, 2019.

 

NOTE 11: SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events for disclosure purposes.

 

10 

 

 

ITEM 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

We discuss expectations regarding our future performance, such as our business outlook, in our annual and quarterly reports, news releases, and other written and oral statements. These “forward-looking statements” are based on currently available competitive, financial and economic data and our operating plans. They are inherently uncertain, and investors must recognize that events could turn out to be significantly different from our expectations and could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions; political, regulatory, tax, competitive and technological developments affecting our operations or the demand for our products, including the imposition of tariffs; timely development and market acceptance of new products and continued customer validation of our coating technologies; adequacy of financing; capacity additions, the ability to enforce patents; maintenance of operating leverage; maintenance of increased order backlog; consummation of order proposals; completion of large orders on schedule and on budget; continued sales growth in the medical and alternative energy markets; successful transition from primarily selling ultrasonic nozzles and components to a more complex business providing complete machine solutions and higher value subsystems; and realization of quarterly and annual revenues within forecasted range.

We undertake no obligation to update any forward-looking statement.

OVERVIEW

Founded in 1975, Sono-Tek Corporation designs and manufactures ultrasonic coating systems that apply precise, thin film coatings to a multitude of products for the microelectronics/electronics, alternative energy, medical and industrial markets, including specialized glass applications in construction and automotive. We also sell our products to emerging research and development and other markets. We have invested significant resources to enhance our market diversity. Using our core ultrasonic coating technology, we have increased our portfolio of products, the industries we serve, and the countries in which we sell our products.

Our ultrasonic nozzle systems use high frequency, ultrasonic vibrations that atomize liquids into minute drops that can be applied to surfaces at low velocity providing thin layers of protective materials over a surface such as glass. Our solutions are environmentally-friendly, efficient and highly reliable. They enable dramatic reductions in overspray, savings in raw material, water and energy usage and provide improved process repeatability, transfer efficiency, high uniformity and reduced emissions.

We believe product superiority is imperative in all that we produce and that it is developed through the extensive experience we have in the coatings industry, our proprietary manufacturing know-how and skills and our unique work force we have built over the years. Our growth strategy is focused on leveraging our innovative technologies, proprietary know-how, unique talent and experience, and global reach to further develop thin film coating technologies that enable better outcomes for our customers’ products and processes.

We are a global business with approximately 65% of our sales generated from outside the United States in the first nine months of fiscal 2020. Our direct sales team and our distributor and sales representative network are located in North America, Latin America, Europe and Asia. Over the last few years, we have expanded our sales capabilities by increasing the size of our direct sales force and adding new distributors and sales representatives (“reps”). Of note, we have implemented demonstration labs in several areas of Asia and Europe, in addition to our headquarters lab in New York, that are used to train our distributors and reps. These labs are also valuable for demonstrating to prospective customers the capabilities of our equipment and enable us to develop custom solutions to meet their needs.

Over the last few years, we have shifted our business from primarily selling our ultrasonic nozzles and components to a more complex business providing complete machine solutions and higher value subsystems to original equipment manufacturers (“OEMs”). The range for our average unit selling price has broadened as a result to $50 thousand per unit to over $240 thousand per unit. As a result, we can experience wide variations in both order flow and shipments from quarter to quarter.

Third Quarter Fiscal 2020 Highlights (compared with the third quarter of fiscal 2019 unless otherwise noted) We refer to the three-month periods ended November 30, 2019 and 2018 as the third quarter of fiscal 2020 and fiscal 2019, respectively.

 

  Net sales were $3,672,000, up 16% or $517,000, primarily driven by increased sales for widetrack integrated coating systems in the float glass market, and increased sales of our SonoBraze product for the manufacturing of heat exchangers and condensers.

 

11 

 

 

  Gross profit margin was 48.9% compared with 41.1%.  Improvement is primarily due to a shift in sales to countries other than China, change in product mix, and increased sales volume of integrated coating systems and multi-axis coating systems.

 

  Operating income increased to $270,000, compared with operating income of $50,000. Growth in revenue and gross profit improved operating income during the quarter.

 

  Backlog on November 30, 2019 continues to be at record levels, up 78% to $5,402,000, compared with a backlog of $3,038,000 on February 28, 2019.

Nine Month Fiscal 2020 Highlights (compared with the first nine months of fiscal 2019 unless otherwise noted) We refer to the nine-month periods ended November 30, 2019 and 2018 as the first nine months of fiscal 2020 and fiscal 2019, respectively.

 

  Net sales were $9,841,000, up 13% or $1,167,000, led by a large increase in sales to the semiconductor industry, increased sales of stent coating systems, and increased sales of float glass coating equipment.

 

  Gross profit margin was 47.2% compared with 45.1%.  Improvement is primarily due to a shift in sales to countries other than China, change in product mix, and increased sales volume of integrated coating systems and multi-axis coating systems.

 

  Operating income increased to $367,000 compared with $96,000.  Growth in revenue and gross profit were key factors in the improvement of operating income during the quarter.  

 

RESULTS OF OPERATIONS

 

Sales

 

Product Sales:

 

   Three Months Ended
November 30,
   Change   Nine Months Ended
November 30,
   Change 
   2019   2018   $   %   2019   2018   $   % 
Fluxing Systems  $261,000   $281,000    (20,000)   (7%)  $863,000   $854,000    9,000    1% 
Integrated Coating Systems   628,000    286,000    342,000    120%    1,438,000    917,000    521,000    57% 
Multi-Axis Coating Systems   1,631,000    1,681,000    (50,000)   (3%)   4,519,000    3,813,000    706,000    19% 
OEM Systems   400,000    402,000    (2,000)       965,000    1,380,000    (415,000)   (30%)
Other   752,000    505,000    247,000    49%    2,056,000    1,710,000    346,000    20% 
TOTAL  $3,672,000   $3,155,000    517,000    16%   $9,841,000   $8,674,000    1,167,000    13% 

 

Sales growth was driven by demand for our more complex, highly-engineered and higher value multi-axis and integrated coating machines, primarily for the Electronics/Microelectronics and Medical markets in the first nine months of fiscal 2020. This equipment’s average selling price can range from $100 thousand to over $300 thousand per unit and is typically ordered in one-or two-unit volumes. Growth in these product categories more than offset the decline in OEM Systems, greatly influenced by our strategy to offer customers full coating solutions at higher price points compared to smaller revenue OEM packages.

 

Market Sales:

 

   Three Months Ended       Nine Months Ended     
   November 30,   Change   November 30,   Change 
   2019   2018   $   %   2019   2018   $   % 
Electronics/Microelectronics  $1,104,000   $1,034,000    70,000    7%   $4,017,000   $3,048,000    969,000    32% 
Medical   1,083,000    644,000    439,000    68%    2,875,000    2,726,000    149,000    5% 
Alternative Energy   917,000    1,061,000    (144,000)   (14%)   1,527,000    1,562,000    (35,000)   (2%)
Emerging R&D and Other   252,000    289,000    (37,000)   (13%)   937,000    974,000    (37,000)   (4%)
Industrial   316,000    127,000    189,000    148%    485,000    364,000    121,000    33% 
TOTAL  $3,672,000   $3,155,000    517,000    16%   $9,841,000   $8,674,000    1,167,000    13% 

 

12 

 

 

Customer use of our application process development laboratories, located throughout the world, continue to reach record levels in the first nine months of fiscal 2020, which we believe demonstrates the success of our strategy to provide excellent application engineering expertise as well as paid coating services to prospects and customers to validate the capabilities of our coating technologies for their uses. These service-based customers are guided by our applications engineering team, to develop successful coating processes for their unique needs. Upon achieving coating results that meet the application requirements, the customer's next step is typically to purchase the newly defined coating solution. We believe a high percentage of prospects and customers that use our lab services to develop their products results in sales of our ultrasonic coating solutions.

 

We experienced a significant increase in the Electronics/Microelectronics market, primarily as a result of sales to the semiconductor market. Sono-Tek continues to make significant investment in both personnel and equipment for focused application engineering expertise in this area.

 

The medical market showed an increase in the first nine months of fiscal 2020 which was primarily influenced by strong sales of our equipment to be used for stent coating.

 

Geographic Sales:

 

   Three Months Ended
November 30,
   Change   Nine Months Ended
November 30,
   Change 
   2019   2018   $   %   2019   2018   $   % 
U.S. & Canada  $1,278,000   $1,211,000    67,000    6%   $3,440,000   $3,283,000    157,000    5% 
Asia Pacific (APAC)   1,372,000    1,368,000    4,000        2,712,000    2,744,000    (32,000)   (1%)
Europe, Middle East, Asia (EMEA)   737,000    440,000    297,000    68%    2,249,000    1,990,000    259,000    13% 
Latin America   285,000    136,000    149,000    110%    1,440,000    657,000    783,000    119% 
TOTAL  $3,672,000   $3,155,000    517,000    16%   $9,841,000   $8,674,000    1,167,000    13% 

 

In both the third quarter and first nine months of fiscal 2020, approximately 65% of sales originated outside of the United States and Canada compared with 62% in the prior-year fiscal periods. The strong increase in sales to Latin America was primarily the result of a significant custom designed multi-axis medical device coating system, and a steady increase of fluxing systems sold into Mexico.

 

Gross Profit:

 

   Three Months Ended
November 30,
   Change   Nine Months Ended
November 30,
   Change 
   2019   2018   $   %   2019   2018   $   % 
Net Sales  $3,672,000   $3,155,000   $517,000    16%   $9,841,000   $8,674,000   $1,167,000    13% 
Cost of Goods Sold   1,875,000    1,859,000    16,000    1%    5,192,000    4,762,000    430,000    9% 
Gross Profit  $1,797,000   $1,296,000   $501,000    39%   $4,649,000   $3,912,000   $737,000    19% 
                                         
Gross Profit %   48.9%    41.1%              47.2%    45.1%           

 

Gross profit increased $501,000, or 39%, to $1,797,000 for the third quarter of fiscal 2020 compared with $1,296,000 in the prior year period. Gross profit margin was 48.9% in the third quarter of fiscal 2020, compared with 41.1% in the prior year period.

 

Gross profit increased $737,000, or 19%, to $4,649,000 for the first nine months of fiscal 2020 compared with $3,912,000 in the prior year period. Gross profit margin was 47.2% for the first nine months of fiscal 2020, compared with 45.1% in the prior year period.

 

The improvement in gross profit margin for the third quarter and the first nine months of fiscal 2020, is partially due to a shift in sales to countries other than China. In the prior fiscal year, our gross profit margin was negatively impacted as a result of our pricing strategy to establish a foothold in the fuel cell market in China. In addition, the shift of sales away from China, has reduced the deep discounts required to sell in China and the avoidance of tariffs which have had a negative impact on our margins.

 

13 

 

 

In addition, in the third quarter and first nine months of fiscal 2020, our gross profit margins were partially improved due to increased sales of our widetrack systems and medicoat stent coating equipment, both of these product lines traditionally have had higher profit margins compared to our other products.

 

Operating Expenses:

 

   Three Months Ended
November 30,
   Change   Nine Months Ended
November 30,
   Change 
   2019   2018   $   %   2019   2018   $   % 
Research and product development  $362,000   $325,000    37,000    11%   $1,020,000   $979,000    41,000    4% 
Marketing and selling   849,000    653,000    196,000    30%    2,326,000    1,979,000    347,000    18% 
General and administrative   316,000    268,000    48,000    18%    936,000    858,000    78,000    9% 
Total Operating Expenses  $1,527,000   $1,246,000   $281,000    23%   $4,282,000   $3,816,000   $466,000    12% 

 

Research and Product Development:

For the third quarter of fiscal 2020, research and product development costs increased primarily due to an increase in research and development materials.

 

For the first nine months of fiscal 2020, research and product development costs increased $41,000 as a result of higher salary expense and related health insurance costs from the addition of personnel and increased research and development materials expense. These expenses were partially offset by decreases in depreciation and travel expense.

 

Marketing and Selling:

Higher marketing and selling costs for the third quarter of fiscal 2020 were the result of increases in salaries and related health insurance premiums, international commission expense and trade show expense.

 

Higher marketing and selling costs for the first nine months of fiscal 2020 were due to increased salaries, health insurance premiums and trade show expense. These increases were partially offset by decreases in travel expense and international distributor training expense.

 

In the third quarter of fiscal 2020, we expended approximately $229,000 for commissions as compared with $116,000 for the prior year fiscal period, an increase of $113,000. For the first nine months of fiscal 2020, we expended approximately $505,000 for commissions as compared with $325,000 for the prior year fiscal period, an increase of $180,000. The increase in commission expense, in both periods, is primarily the result of an increase in international sales being generated by our external distributors. Our external distributors are commissioned at a higher rate than our in house sales team.

 

General and Administrative:

Higher general and administrative costs in the third quarter and the first nine months of fiscal 2020 were the result of increases in health insurance premiums, corporate expense and stock-based compensation expense. These increases were partially offset by lower professional fees, supplies and other miscellaneous expenses.

 

Health Insurance Premiums:

The Company’s health insurance program requires employee contributions. In the third quarter of fiscal 2020, the Company’s net health insurance expense was approximately $94,000 as compared with $88,000 for the prior year fiscal period, an increase of $6,000 or 7%.

 

For the first nine months of fiscal 2020, the Company’s net health insurance expense was approximately $285,000 as compared with $234,000 for the prior year fiscal period, an increase of $51,000 or 22%. The increase in health insurance expense for the first nine months of fiscal 2020 is primarily attributable to the timing of the Company’s insurance program renewal and eligible employee enrollment.

 

Operating Income:

Our operating income increased $220,000, to $270,000 in the third quarter of fiscal 2020, compared with $50,000 for the prior year period. Growth in revenue and gross profit were key factors in the improvement of operating income in the third quarter of fiscal 2020. Operating margin for the quarter increased to 7.4% compared with 1.6% in the prior year period.

 

14 

 

 

For the first nine months of fiscal 2020, operating income increased $271,000, to $367,000 compared with $96,000 in the prior year period. Growth in revenue and related growth in gross profit were key factors in the improvement of operating income in the first nine months of fiscal 2020. Operating margin for the first nine months of fiscal 2020 increased to 3.7% compared with 1.1% in the prior year period. We continue to invest in research and product development, as well as marketing and selling activities as well as professional and other staffing to support our anticipated future market opportunities.

 

Interest Expense:

Interest expense was $8,000 in the third fiscal quarter of 2020 compared with $10,000 for the prior-year period. For the first nine months of fiscal 2020, interest expense was $25,000 compared with $31,000 for the prior year period. Interest expense is directly related to the mortgage on our industrial park.

 

Interest and Dividend Income:

Interest and dividend income decreased $12,000 to $21,000 in the third quarter of fiscal 2020 as compared with $33,000 for the prior year period. For the first nine months of fiscal 2020, interest and dividend income decreased $28,000 to $77,000 as compared with $105,000 in the prior year period. The decrease in interest and dividend income, in both periods, is due to the reallocation of our investments into US Treasury securities and certificates of deposit.

 

Our present investment policy is to invest excess cash in highly liquid, low risk US Treasury securities, certificates of deposit and mutual funds. At November 30, 2019, the majority of our holdings are rated at or above investment grade.

 

Net unrealized loss on marketable securities:

The Company adopted ASU 2016-01, “Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” in the first quarter of fiscal 2019. ASU 2016-01 requires the Company to measure its equity investments at fair value and changes in fair value are to be recognized in net income. Further information is available in NOTE 2: SIGNIFICANT ACCOUNTING POLICIES in our financial statements.

 

In the third quarter and the first nine months of fiscal 2019, net income and earnings per share reflect the actual deduction of $59,000 and $189,000, respectively, for the unrealized loss on our marketable securities.

 

In the third quarter and the first nine months of fiscal 2020, there was no unrealized gain or loss recorded for the Company’s marketable securities. Our present investment policy is to invest excess cash in highly liquid, low risk US Treasury securities, certificates of deposit and mutual funds. Unrealized gains or losses, if any, are considered to be immaterial.

 

Other Income:

Included in other income is the net revenue related to the rental of the Company’s real estate.

 

For the third quarter of fiscal 2020, the Company’s rental revenue was $20,000, expenses were $13,000 and net revenue was $7,000. This compares with the third quarter of fiscal 2019 when rental revenue was $22,000, expenses were $13,000 and net revenue was $9,000.

 

For the first nine months of fiscal 2020, the Company’s rental revenue was $60,000, expenses were $41,000 and net revenue was $19,000. This compares with the first nine months of fiscal 2019 when rental revenue was $63,000, expenses were $43,000 and net revenue was $20,000.

 

Income Tax Expense:

We recorded income tax expense of $10,000 for the third quarter of fiscal 2020 compared with $3,000 for the prior year period.

 

We recorded income tax expense of $23,000 for the first nine months of fiscal 2020 compared with $28,000 for the prior year period.

 

Net Income:

Net income increased by $260,000 to $280,000 for the third quarter of fiscal 2020 compared with $20,000 for the prior fiscal period.

 

Net income increased by $319,000 to $420,000 for the first nine months of fiscal 2020 compared with $101,000 for the prior year period.

 

15 

 

 

Fiscal Year 2020 Outlook

 

We expect that a significant portion of our backlog of $5,402,000, as of November 30, 2019, will ship during the fiscal year ending February 29, 2020. However, shipments are dependent upon customer acceptance test schedules for some of our more complex and customized equipment orders. Based on our existing backlog, we expect that our current fiscal year sales will grow in the range of 15% to 25%. Furthermore, we expect that this increased sales volume will expand margins and drive stronger earnings. Part of our anticipated growth is due to a $1,650,000 order for one of Sono-Tek’s newly developed Robotic Coating Platforms called OMNIbot. OMNIbot is a product line that will allow us to pursue additional prospects for customers’ six-axis robotic coating needs, which presents an opportunity for additional growth.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Working Capital – Our working capital increased $272,000 to $6,696,000 at November 30, 2019 from $6,424,000 at February 28, 2019. The increase in working capital was mostly the result of the current period's net income and noncash charges partially offset by purchases of equipment and repayment of long-term debt.

 

The Company aggregates cash and cash equivalents and marketable securities in managing its balance sheet and liquidity. For purposes of the following analysis, the total is referred to as “Cash.” At November 30, 2019 and February 28, 2019, our working capital included:

 

    November 30,
2019
    February 28,
2019
    Cash
(Decrease)
Increase
 
Cash and cash equivalents   $ 2,279,000     $ 3,144,000     ($ 865,000 )
Marketable securities     3,740,000       2,366,000       1,374,000  
Total   $ 6,019,000     $ 5,510,000      $ 509,000  

 

The following table summarizes the accounts and the major reasons for the $509,000 increase in “Cash”:

 

 

  Impact on Cash   Reason
Net income, adjusted for non-cash items $ 841,000   To reconcile increase in cash.
Accounts receivable decrease   60,000   Cash receipts.
Inventories increase   (1,370,000)   Required to support backlog.
Prepaid expense decrease   201,000   Previous deposits on inventory.
Equipment purchases   (392,000)   Equipment upgrade for productivity.
Customer deposits increase   804,000   Received for new orders.
Accounts payable increase   469,000   Timing of disbursements.
Repayment of long-term debt   (122,000)   Repayment of debt.
Taxes payable increase   18,000   Timing of disbursements.
Net increase in cash $ 509,000    

 

Stockholders’ Equity – Stockholder’s Equity increased $501,000 to $9,086,000 at November 30, 2019, from $8,585,000 at February 28, 2019. The increase was a result of the current period’s net income of $420,000 and stock-based compensation expense of $81,000.

 

Operating Activities – We generated $1,023,000 of cash in our operating activities in the first nine months of fiscal 2020 compared with $88,000 in the first nine months of fiscal 2019. The increase in cash generated by operating activities was mostly the result of increased accounts payable, accrued expenses, customer deposits and a decrease in accounts receivable. These sources of cash were partially offset by increased inventories and a decrease in prepaid expenses directly related to inventory.

 

Investing Activities – For the first nine months of fiscal 2020, cash used by investing activities was $1,766,000 compared with using $361,000 of cash for the first nine months of fiscal 2019. For the first nine months of fiscal years 2020 and 2019, we used $392,000 and $487,000, respectively, for the purchase or manufacture of equipment, furnishings and leasehold improvements. For the first nine months of fiscal 2020, we used $1,374,000 for the purchase of marketable securities and for the first nine months of fiscal 2019 we received $126,000 from the sale of marketable securities.

 

16 

 

 

Financing Activities – In the first nine months of fiscal years 2020 and 2019, we used $122,000 and $117,000 in cash, respectively, for the repayment of our note payable.

 

Net (Decrease) in Cash and Cash Equivalents – In the first nine months of fiscal 2020 our cash balance decreased by $865,000 compared with a decrease of $390,000 in the first nine months of fiscal 2019. In the first nine months of fiscal 2020, our operating activities generated $1,023,000 of cash. In addition, we used $392,000 for the purchase or manufacture of equipment, furnishings and leasehold improvements, used $1,374,000 for the purchase of marketable securities and used $122,000 for the repayment of our note payable.

 

CRITICAL ACCOUNTING POLICIES

 

The discussion and analysis of the Company’s financial condition and results of operations are based upon the consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amount of assets and liabilities, revenues and expenses, and related disclosure on contingent assets and liabilities at the date of the financial statements. Actual results may differ from these estimates under different assumptions and conditions.

 

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and may potentially result in materially different results under different assumptions and conditions. The Company believes that critical accounting policies are limited to those described below. For a detailed discussion on the application of these and other accounting policies see Note 2 to the Company’s consolidated financial statements included in Form 10-K for the year ended February 28, 2019.

 

Accounting for Income Taxes

As part of the process of preparing the Company’s condensed consolidated financial statements, the Company is required to estimate its income taxes. Management judgment is required in determining the provision for the deferred tax asset.

 

Stock-Based Compensation

The computation of the expense associated with stock-based compensation requires the use of a valuation model. ASC 718 is a complex accounting standard, the application of which requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility, expected option lives, and expected option forfeiture rates, to value equity-based compensation. The Company currently uses a Black-Scholes option pricing model to calculate the fair value of its stock options. The Company primarily uses historical data to determine the assumptions to be used in the Black-Scholes model and has no reason to believe that future data is likely to differ materially from historical data. However, changes in the assumptions to reflect future stock price volatility and future stock award exercise experience could result in a change in the assumptions used to value awards in the future and may result in a material change to the fair value calculation of stock-based awards. ASC 718 requires the recognition of the fair value of stock compensation in net income. Although every effort is made to ensure the accuracy of our estimates and assumptions, significant unanticipated changes in those estimates, interpretations and assumptions may result in recording stock option expense that may materially impact our financial statements for each respective reporting period.

 

IMPACT OF NEW ACCOUNTING PRONOUNCEMENTS

 

For information regarding new accounting pronouncements and their effect on the Company, see “New Accounting Pronouncements” in Note 2 of the unaudited notes to the condensed consolidated financial statements.

 

ITEM 3 - Quantitative and Qualitative Disclosures about Market Risk

 

The Company does not issue or invest in financial instruments or derivatives for trading or speculative purposes. Substantially all of the operations of the Company are conducted in the United States, and, as such, are not subject to material foreign currency exchange rate risk. All of our sales transactions are completed in US dollars.

 

Although the Company's assets included $2,279,000 in cash and $3,740,000 in marketable securities, the market rate risk associated with changing interest rates in the United States is not material.

 

17 

 

 

ITEM 4 – Controls and Procedures

 

The Company has established and maintains “disclosure controls and procedures” (as those terms are defined in Rules 13a –15(e) and 15d-15(e) under the Securities and Exchange Act of 1934 (the “Exchange Act”). Christopher L. Coccio, Chief Executive Officer (principal executive) and Stephen J. Bagley, Chief Financial Officer (principal accounting officer) of the Company, have evaluated the Company’s disclosure controls and procedures as of November 30, 2019. Based on this evaluation, they have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (2) accumulated and communicated to Management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding timely disclosure.

 

In addition, there were no changes in the Company’s internal controls over financial reporting during the third fiscal quarter of 2020 that have materially affected, or are reasonably likely to materially affect, internal controls over financial reporting.

 

18 

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings
  None
   
Item 1A. Risk Factors
  Note Required for Smaller Reporting Companies
   
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
  None
   
Item 3. Defaults Upon Senior Securities
  None
   
Item 4. Mine Safety Disclosures
  None
   
Item 5. Other Information
  None
   
Item 6. Exhibits and Reports
   
  31.131.2– Rule 13a - 14(a)/15d – 14(a) Certification
   
  32.132.2 – Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
   
  101.INS – XBRL Instance Document.
   
  101.SCH – XBRL Taxonomy Extension Schema Document
   
  101.CAL – XBRL Taxonomy Calculation Linkbase Document
   
  101.DEF – XBRL Taxonomy Extension Definition Linkbase Document
   
  101.LAB – XBRL Extension Label Linkbase Document
   
  101.PRE – XBRL Taxonomy Extension Presentation Linkbase Document

 

19 

 

 

SIGNATURES

 

 

In accordance with the requirements of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: January 14, 2020

 

    SONO-TEK CORPORATION
                  (Registrant)
     
     
  By: /s/ Christopher L. Coccio
    Christopher L. Coccio
    Chief Executive Officer
     
     
     
  By: /s/ Stephen J. Bagley
    Stephen J. Bagley
    Chief Financial Officer

 

 

20